Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience-Reference-Cited by-同舟云学术

Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience

Published:2022-06-22 Issue:8 Volume:101 Page:1769-1776
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Beyar-Katz Ofrat^ORCID,Perry Chava,On Yael Bar,Amit Odelia,Gutwein Odit,Wolach Ofir,Kedar Rotem,Pikovsky Oleg,Avivi Irit,Gold Ronit,Ben-Ezra Jonathan,Shasha David,Ami Ronen Ben,Ram Ron

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-022-04889-6.pdf

Reference26 articles.

1. Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML et al (2020) DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv 4(13):3024–3033

2. Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643–1650

3. Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A et al (2020) Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma 61(4):940–943

4. Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P et al (2021) Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study. Haematologica 107(5):1111–1118

5. Center for International Blood and Marrow Transplant Research. Cellular therapy manuals-peripheral blood count recovery. https://www.cibmtr.org/manuals/fim/1/en/topic/4100q17-20

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients;Journal of Clinical Medicine;2024-08-28

2. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review;European Journal of Cancer;2024-07

3. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma;Frontiers in Oncology;2024-06-11

4. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies;Current Opinion in Supportive & Palliative Care;2024-04-23

5. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study);Blood Advances;2024-03-26